These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6818093)

  • 1. Distribution and excretion of 7-N-(p-hydroxyphenyl)-mitomycin C in normal mice.
    Imai R; Morimoto M; Marumo H
    Gan; 1982 Aug; 73(4):675-80. PubMed ID: 6818093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
    Fujita H
    Gan To Kagaku Ryoho; 1982 Aug; 9(8):1362-73. PubMed ID: 6820913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.
    Imai R; Morimoto M; Marumo H; Kobayashi T; Tsuruo T; Inaba M; Tsukagoshi S; Sakurai Y
    Gan; 1981 Dec; 72(6):944-9. PubMed ID: 6804296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced lymphatic delivery of mitomycin C conjugated with dextran.
    Takakura Y; Matsumoto S; Hashida M; Sezaki H
    Cancer Res; 1984 Jun; 44(6):2505-10. PubMed ID: 6202398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of mitomycin C in humans.
    den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
    Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of intraarterial mitomycin C in humans.
    Hu E; Howell SB
    Cancer Res; 1983 Sep; 43(9):4474-7. PubMed ID: 6409404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
    van Hazel GA; Scott M; Rubin J; Moertel CG; Eagan RT; O'Connell MJ; Kovach JS
    Cancer Treat Rep; 1983 Sep; 67(9):805-10. PubMed ID: 6411337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topical application of mitomycin C conjugated with dextran (MMC-D): a high molecular weight derivative of mitomycin C].
    Honda K; Satomura K; Hashida M; Sezaki H
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):530-5. PubMed ID: 2408576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the hematologic toxicity of 7-N-(p-hydroxyphenyl),-mitomycin C and mitomycin C.
    Kobayashi T; Inaba M; Tsukagoshi S; Sakurai Y; Imai R; Morimoto M
    Gan; 1981 Dec; 72(6):950-4. PubMed ID: 6804297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The action of 7-N-(p-hydroxyphenyl)mitomycin C [M-83] in suppressing murine immune response.
    Okabe M; Imai R; Morimoto M
    J Antibiot (Tokyo); 1982 Aug; 35(8):1055-62. PubMed ID: 6754673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
    Takahashi K; Yokoyama M; Takahashi H; Wakui A
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced anticancer efficacy by use of mitomycin C adsorbed on small activated carbon particles in mice.
    Hagiwara A; Takahashi T; Ueda T; Nakagawa Y
    Jpn J Cancer Res; 1987 Apr; 78(4):405-8. PubMed ID: 3108220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice.
    Asanuma F
    J Antibiot (Tokyo); 1985 Mar; 38(3):401-10. PubMed ID: 4008332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the physiological disposition and pharmacokinetics of 7-N-(p-hydroxyphenyl)-mitomycin C].
    Okumura S; Deguchi T; Nakamizo N
    Jpn J Antibiot; 1982 Aug; 35(8):1967-76. PubMed ID: 7154244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
    Ogura T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 2):689-96. PubMed ID: 3083782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
    Sato M; Onishi H; Takahara J; Machida Y; Nagai T
    Biol Pharm Bull; 1996 Sep; 19(9):1170-7. PubMed ID: 8889036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition and pharmacokinetics of a polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate, in the rat.
    Hashida M; Kato A; Takakura Y; Sezaki H
    Drug Metab Dispos; 1984; 12(4):492-9. PubMed ID: 6148218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect on immunological response of host by mitomycin C adsorbed into activated carbon particles (MMC-CH) in mice].
    Iwamoto A; Sakita M; Hata K; Hagiwara A; Takahashi T
    Nihon Geka Gakkai Zasshi; 1989 Nov; 90(11):1829-33. PubMed ID: 2514342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polybutylcyanoacrylate nanoparticles as a carrier for mitomycin C in rabbits bearing VX2-liver tumor.
    Xi-Xiao Y; Jan-Hai C; Shi-Ting L; Dan G; Xv-Xin Z
    Regul Toxicol Pharmacol; 2006 Dec; 46(3):211-7. PubMed ID: 17010489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
    Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
    J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.